Loading…

Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy

The purpose was to evaluate the efficacy of treatment and the occurrence of aggression-related adverse events among children receiving perampanel (PER) with concomitant levetiracetam (LEV). Patients were selected according to the following criteria: 1) between 12 and 18 years old; 2) seizures refrac...

Full description

Saved in:
Bibliographic Details
Published in:European journal of paediatric neurology 2019-01, Vol.23 (1), p.197-203
Main Authors: Kanemura, Hideaki, Sano, Fumikazu, Aihara, Masao
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c400t-2d97f2a47021c8257d31a2bed361c299d0d35a244eae6ada658ac990956349203
cites cdi_FETCH-LOGICAL-c400t-2d97f2a47021c8257d31a2bed361c299d0d35a244eae6ada658ac990956349203
container_end_page 203
container_issue 1
container_start_page 197
container_title European journal of paediatric neurology
container_volume 23
creator Kanemura, Hideaki
Sano, Fumikazu
Aihara, Masao
description The purpose was to evaluate the efficacy of treatment and the occurrence of aggression-related adverse events among children receiving perampanel (PER) with concomitant levetiracetam (LEV). Patients were selected according to the following criteria: 1) between 12 and 18 years old; 2) seizures refractory to at least 2 first-line drugs; 3) at least 4 seizures a month before PER administration; and 4) at least 12 months of follow-up. Patients were subdivided into groups with and without LEV as concomitant treatment. PER was administered at a dose of 2 mg/day, increasing by 2 mg/day every 2 weeks up to 12 mg/day if seizures appeared. In comparison with the baseline seizure frequency, response to PER treatment was classified as follows: complete cessation (100% seizure control); response (≥50% reduction in seizures); and exacerbation (≥50% increase in seizures). Responders were identified as patients showing complete cessation or response. The study group comprised 39 outpatients with a mean age of 13.7 years at enrollment. Responder status was seen in 13 of the 19 patients with LEV and 4 of the 20 patients without LEV. PER appeared significantly more effective in patients with LEV than in those without LEV (p = 0.0076). Seizure-free status was significantly more frequent among patients with LEV (47.4%) than among those without LEV (15.0% (p = 0.0407)). Aggression was present in 2 patients without LEV, but none with LEV. The present study suggests the utility of PER with concomitant LEV for children with drug-resistant epilepsy. •We investigated the usefulness among children receiving PER with concomitant LEV.•PER appeared more effective in patients with LEV than in those without LEV.•Seizure-free status was significantly more frequent among patients with LEV.•Aggression was present in 2 patients without LEV, but none with LEV.•The present study suggests the utility of PER with concomitant LEV for children.
doi_str_mv 10.1016/j.ejpn.2018.10.004
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2133432519</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1090379818303064</els_id><sourcerecordid>2133432519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-2d97f2a47021c8257d31a2bed361c299d0d35a244eae6ada658ac990956349203</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMoVqt_wIPs0cvWycduG_AixS8oeLHnkCazmrJfJtlK_72prR49zTA888L7EHJFYUKBlrfrCa77dsKAztJhAiCOyBktOMsZ5XCcdpCQ86mcjch5CGsAkIKVp2TEQTAhJZwRvQxYDXWLIWRdlfXoddPrFuvsy8WPzHSt6RoXdRuzGjcYndcGo26yqvNZr6PDNoY9a_3wnnsMLvzg2Lsa-7C9ICeVrgNeHuaYLB8f3ubP-eL16WV-v8iNAIg5s3JaMS2mwKiZsWJqOdVshZaX1DApLVheaCYEaiy11WUx0yZVkEXJhWTAx-Rmn9v77nPAEFXjgsG6Tm26IajkhAvOCioTyvao8V0IHivVe9dov1UU1E6tWqudWrVTu7sltenp-pA_rBq0fy-_LhNwtwcwtdw49CqYpMegdR5NVLZz_-V_A2P-i8g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2133432519</pqid></control><display><type>article</type><title>Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Kanemura, Hideaki ; Sano, Fumikazu ; Aihara, Masao</creator><creatorcontrib>Kanemura, Hideaki ; Sano, Fumikazu ; Aihara, Masao</creatorcontrib><description>The purpose was to evaluate the efficacy of treatment and the occurrence of aggression-related adverse events among children receiving perampanel (PER) with concomitant levetiracetam (LEV). Patients were selected according to the following criteria: 1) between 12 and 18 years old; 2) seizures refractory to at least 2 first-line drugs; 3) at least 4 seizures a month before PER administration; and 4) at least 12 months of follow-up. Patients were subdivided into groups with and without LEV as concomitant treatment. PER was administered at a dose of 2 mg/day, increasing by 2 mg/day every 2 weeks up to 12 mg/day if seizures appeared. In comparison with the baseline seizure frequency, response to PER treatment was classified as follows: complete cessation (100% seizure control); response (≥50% reduction in seizures); and exacerbation (≥50% increase in seizures). Responders were identified as patients showing complete cessation or response. The study group comprised 39 outpatients with a mean age of 13.7 years at enrollment. Responder status was seen in 13 of the 19 patients with LEV and 4 of the 20 patients without LEV. PER appeared significantly more effective in patients with LEV than in those without LEV (p = 0.0076). Seizure-free status was significantly more frequent among patients with LEV (47.4%) than among those without LEV (15.0% (p = 0.0407)). Aggression was present in 2 patients without LEV, but none with LEV. The present study suggests the utility of PER with concomitant LEV for children with drug-resistant epilepsy. •We investigated the usefulness among children receiving PER with concomitant LEV.•PER appeared more effective in patients with LEV than in those without LEV.•Seizure-free status was significantly more frequent among patients with LEV.•Aggression was present in 2 patients without LEV, but none with LEV.•The present study suggests the utility of PER with concomitant LEV for children.</description><identifier>ISSN: 1090-3798</identifier><identifier>EISSN: 1532-2130</identifier><identifier>DOI: 10.1016/j.ejpn.2018.10.004</identifier><identifier>PMID: 30424990</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Aggression ; Children ; Concomitant treatment ; Drug-resistant epilepsy ; Levetiracetam (LEV) ; Perampanel (PER)</subject><ispartof>European journal of paediatric neurology, 2019-01, Vol.23 (1), p.197-203</ispartof><rights>2018 European Paediatric Neurology Society</rights><rights>Copyright © 2018 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-2d97f2a47021c8257d31a2bed361c299d0d35a244eae6ada658ac990956349203</citedby><cites>FETCH-LOGICAL-c400t-2d97f2a47021c8257d31a2bed361c299d0d35a244eae6ada658ac990956349203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30424990$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kanemura, Hideaki</creatorcontrib><creatorcontrib>Sano, Fumikazu</creatorcontrib><creatorcontrib>Aihara, Masao</creatorcontrib><title>Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy</title><title>European journal of paediatric neurology</title><addtitle>Eur J Paediatr Neurol</addtitle><description>The purpose was to evaluate the efficacy of treatment and the occurrence of aggression-related adverse events among children receiving perampanel (PER) with concomitant levetiracetam (LEV). Patients were selected according to the following criteria: 1) between 12 and 18 years old; 2) seizures refractory to at least 2 first-line drugs; 3) at least 4 seizures a month before PER administration; and 4) at least 12 months of follow-up. Patients were subdivided into groups with and without LEV as concomitant treatment. PER was administered at a dose of 2 mg/day, increasing by 2 mg/day every 2 weeks up to 12 mg/day if seizures appeared. In comparison with the baseline seizure frequency, response to PER treatment was classified as follows: complete cessation (100% seizure control); response (≥50% reduction in seizures); and exacerbation (≥50% increase in seizures). Responders were identified as patients showing complete cessation or response. The study group comprised 39 outpatients with a mean age of 13.7 years at enrollment. Responder status was seen in 13 of the 19 patients with LEV and 4 of the 20 patients without LEV. PER appeared significantly more effective in patients with LEV than in those without LEV (p = 0.0076). Seizure-free status was significantly more frequent among patients with LEV (47.4%) than among those without LEV (15.0% (p = 0.0407)). Aggression was present in 2 patients without LEV, but none with LEV. The present study suggests the utility of PER with concomitant LEV for children with drug-resistant epilepsy. •We investigated the usefulness among children receiving PER with concomitant LEV.•PER appeared more effective in patients with LEV than in those without LEV.•Seizure-free status was significantly more frequent among patients with LEV.•Aggression was present in 2 patients without LEV, but none with LEV.•The present study suggests the utility of PER with concomitant LEV for children.</description><subject>Aggression</subject><subject>Children</subject><subject>Concomitant treatment</subject><subject>Drug-resistant epilepsy</subject><subject>Levetiracetam (LEV)</subject><subject>Perampanel (PER)</subject><issn>1090-3798</issn><issn>1532-2130</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMoVqt_wIPs0cvWycduG_AixS8oeLHnkCazmrJfJtlK_72prR49zTA888L7EHJFYUKBlrfrCa77dsKAztJhAiCOyBktOMsZ5XCcdpCQ86mcjch5CGsAkIKVp2TEQTAhJZwRvQxYDXWLIWRdlfXoddPrFuvsy8WPzHSt6RoXdRuzGjcYndcGo26yqvNZr6PDNoY9a_3wnnsMLvzg2Lsa-7C9ICeVrgNeHuaYLB8f3ubP-eL16WV-v8iNAIg5s3JaMS2mwKiZsWJqOdVshZaX1DApLVheaCYEaiy11WUx0yZVkEXJhWTAx-Rmn9v77nPAEFXjgsG6Tm26IajkhAvOCioTyvao8V0IHivVe9dov1UU1E6tWqudWrVTu7sltenp-pA_rBq0fy-_LhNwtwcwtdw49CqYpMegdR5NVLZz_-V_A2P-i8g</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Kanemura, Hideaki</creator><creator>Sano, Fumikazu</creator><creator>Aihara, Masao</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201901</creationdate><title>Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy</title><author>Kanemura, Hideaki ; Sano, Fumikazu ; Aihara, Masao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-2d97f2a47021c8257d31a2bed361c299d0d35a244eae6ada658ac990956349203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aggression</topic><topic>Children</topic><topic>Concomitant treatment</topic><topic>Drug-resistant epilepsy</topic><topic>Levetiracetam (LEV)</topic><topic>Perampanel (PER)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kanemura, Hideaki</creatorcontrib><creatorcontrib>Sano, Fumikazu</creatorcontrib><creatorcontrib>Aihara, Masao</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of paediatric neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kanemura, Hideaki</au><au>Sano, Fumikazu</au><au>Aihara, Masao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy</atitle><jtitle>European journal of paediatric neurology</jtitle><addtitle>Eur J Paediatr Neurol</addtitle><date>2019-01</date><risdate>2019</risdate><volume>23</volume><issue>1</issue><spage>197</spage><epage>203</epage><pages>197-203</pages><issn>1090-3798</issn><eissn>1532-2130</eissn><abstract>The purpose was to evaluate the efficacy of treatment and the occurrence of aggression-related adverse events among children receiving perampanel (PER) with concomitant levetiracetam (LEV). Patients were selected according to the following criteria: 1) between 12 and 18 years old; 2) seizures refractory to at least 2 first-line drugs; 3) at least 4 seizures a month before PER administration; and 4) at least 12 months of follow-up. Patients were subdivided into groups with and without LEV as concomitant treatment. PER was administered at a dose of 2 mg/day, increasing by 2 mg/day every 2 weeks up to 12 mg/day if seizures appeared. In comparison with the baseline seizure frequency, response to PER treatment was classified as follows: complete cessation (100% seizure control); response (≥50% reduction in seizures); and exacerbation (≥50% increase in seizures). Responders were identified as patients showing complete cessation or response. The study group comprised 39 outpatients with a mean age of 13.7 years at enrollment. Responder status was seen in 13 of the 19 patients with LEV and 4 of the 20 patients without LEV. PER appeared significantly more effective in patients with LEV than in those without LEV (p = 0.0076). Seizure-free status was significantly more frequent among patients with LEV (47.4%) than among those without LEV (15.0% (p = 0.0407)). Aggression was present in 2 patients without LEV, but none with LEV. The present study suggests the utility of PER with concomitant LEV for children with drug-resistant epilepsy. •We investigated the usefulness among children receiving PER with concomitant LEV.•PER appeared more effective in patients with LEV than in those without LEV.•Seizure-free status was significantly more frequent among patients with LEV.•Aggression was present in 2 patients without LEV, but none with LEV.•The present study suggests the utility of PER with concomitant LEV for children.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30424990</pmid><doi>10.1016/j.ejpn.2018.10.004</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1090-3798
ispartof European journal of paediatric neurology, 2019-01, Vol.23 (1), p.197-203
issn 1090-3798
1532-2130
language eng
recordid cdi_proquest_miscellaneous_2133432519
source ScienceDirect Freedom Collection 2022-2024
subjects Aggression
Children
Concomitant treatment
Drug-resistant epilepsy
Levetiracetam (LEV)
Perampanel (PER)
title Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T08%3A07%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Usefulness%20of%20perampanel%20with%20concomitant%20levetiracetam%20for%20patients%20with%20drug-resistant%20epilepsy&rft.jtitle=European%20journal%20of%20paediatric%20neurology&rft.au=Kanemura,%20Hideaki&rft.date=2019-01&rft.volume=23&rft.issue=1&rft.spage=197&rft.epage=203&rft.pages=197-203&rft.issn=1090-3798&rft.eissn=1532-2130&rft_id=info:doi/10.1016/j.ejpn.2018.10.004&rft_dat=%3Cproquest_cross%3E2133432519%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c400t-2d97f2a47021c8257d31a2bed361c299d0d35a244eae6ada658ac990956349203%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2133432519&rft_id=info:pmid/30424990&rfr_iscdi=true